Kedrion Biopharma Inc.
Kedrion Biopharma Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2001, the company has established itself as a leader in the development and production of high-quality plasma-derived therapies, catering to patients with rare and chronic conditions. Kedrion's core offerings include immunoglobulins, clotting factors, and albumin, all distinguished by their rigorous quality standards and commitment to patient safety. With a strong focus on innovation and sustainability, Kedrion has achieved significant milestones, including strategic partnerships and expansions that enhance its market position. The company is dedicated to improving patient outcomes and continues to make strides in the biopharmaceutical landscape.
DitchCarbon Score
How does Kedrion Biopharma Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kedrion Biopharma Inc.'s score of 35 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kedrion Biopharma Inc.'s reported carbon emissions
In 2024, Kedrion Biopharma Inc. reported total carbon emissions of approximately 26,122,000 kg CO2e for Scope 1 and about 54,381,000 kg CO2e for Scope 2 (market-based), resulting in a combined total of around 80,503,000 kg CO2e for both scopes. This marks a reduction from 2023, where emissions were approximately 27,731,000 kg CO2e for Scope 1 and about 51,432,000 kg CO2e for Scope 2 (market-based), totalling around 79,163,000 kg CO2e. Kedrion's emissions data is cascaded from its parent company, Kedrion Holding Spa, reflecting a commitment to sustainability within its corporate family. The company has initiated a Net Zero Programme targeting reductions in both Scope 1 and Scope 2 emissions, with a timeframe set from 2023 to 2025. While specific percentage reduction targets have not been disclosed, the programme aims to implement strategies that contribute to environmental safeguarding. The company has consistently reported emissions data for Scope 1 and Scope 2, but does not currently disclose Scope 3 emissions. Kedrion's ongoing efforts and commitments highlight its dedication to addressing climate change and reducing its carbon footprint in the biopharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 32,736,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 21,143,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kedrion Biopharma Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
